Highlights
- •Haploidentical transplantation expands the donor pool for sickle cell anemia patients.
- •GVHD is mitigated by two methods: 1. ex-vivo and 2. in vivo T-cell depletion.
- •Graft failure is reduced by the modifications to the conditioning regimens.
- •New desensitization protocols can reduce levels of donor-specific anti-HLA antibodies.
- •Reduced intensity conditioning, mixed chimerism reduce toxicities with good outcomes.
Abstract
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceReferences
- Mortality in sickle cell disease. Life expectancy and risk factors for early death.N Engl J Med. 1994; 330: 1639-1644https://doi.org/10.1056/NEJM199406093302303
- Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease.Blood. 2007; 110: 2749-2756https://doi.org/10.1182/blood-2007-03-079665
- Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease.Biol Blood Marrow Transpl. 2010; 16: 263-272https://doi.org/10.1016/j.bbmt.2009.10.005
- Bone marrow transplantation in sickle cell anemia.Curr Opin Oncol. 2001; 13: 85-90https://doi.org/10.1097/00001622-200103000-00001
- Pulmonary complications of sickle cell disease.N Engl J Med. 2008; 359: 2254-2265https://doi.org/10.1056/NEJMra0804411
- Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients.Med (Baltim). 2005; 84: 363-376https://doi.org/10.1097/01.md.0000189089.45003.52
- Definitions of the phenotypic manifestations of sickle cell disease.Am J Hematol. 2010; 85: 6-13https://doi.org/10.1002/ajh.21550
- Circumstances of death in adult sickle cell disease patients.Am J Hematol. 2006; 81: 858-863https://doi.org/10.1002/ajh.20685
- Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease.Am J Hematol. 2010; 85: 36-40https://doi.org/10.1002/ajh.21569
- Hematopoietic cell transplantation: a curative option for sickle cell disease.Pedia Hematol Oncol. 2007; 24: 569-575https://doi.org/10.1080/08880010701640531
- Blood and marrow transplantation for sickle cell disease: overcoming barriers to success.Curr Opin Oncol. 2009; 21: 158-161https://doi.org/10.1097/CCO.0b013e328324ba04
- Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey.Arch Intern Med. 2002; 162: 929-935https://doi.org/10.1001/archinte.162.8.929
- Unequal treatment: confronting racial and ethnic disparities in health care.J Natl Med Assoc. 2002; 94: 666-668
- Sickle cell disease summit: from clinical and research disparity to action.Am J Hematol. 2009; 84: 39-45https://doi.org/10.1002/ajh.21315
- Do children with sickle cell disease receive disparate care for pain in the emergency department.J Emerg Med. 2010; 39: 691-695https://doi.org/10.1016/j.jemermed.2009.06.003
- HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.N Engl J Med. 2014; 371: 339-348https://doi.org/10.1056/NEJMsa1311707
- Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.N Engl J Med. 1989; 320: 197-204https://doi.org/10.1056/NEJM198901263200401
- Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.Biol Blood Marrow Transpl. 2001; 7: 665-673https://doi.org/10.1053/bbmt.2001.v7.pm11787529
- Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative.Biol Blood Marrow Transpl. 2019; 25: 1197-1209https://doi.org/10.1016/j.bbmt.2018.11.027
- HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.Blood. 2012; 120: 4285-4291https://doi.org/10.1182/blood-2012-07-438408
- Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.Lancet Haematol. 2019; 6: e183-e193https://doi.org/10.1016/S2352-3026(19)30031-6
- Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.Blood Adv. 2017; 1: 652-661https://doi.org/10.1182/bloodadvances.2016002972
- Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease.Biol Blood Marrow Transpl. 2018; 24: 1759-1765https://doi.org/10.1016/j.bbmt.2018.03.031
Suradej Hongeng, Pakakasama S., Anurathapan U., Andersson B.S. Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Pre-Transplant Immunosuppression and Post-Transplant Cyclophosphamide (Post-Cy) in Severe Thalassemia: A Novel Approach Transplant for Nonmalignant Diseases BMT TANDEM Meeting. San Diego, California: Biology of Blood and Marrow Transplantation; 2015. p. S32.
- HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease.Biol Blood Marrow Transpl. 2018; 24: 185-189https://doi.org/10.1016/j.bbmt.2017.08.039
- The evolution of T cell depleted haploidentical transplantation.Front Immunol. 2019; 10: 2769https://doi.org/10.3389/fimmu.2019.02769
- Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia.Br J Haematol. 2014; 165: 688-698https://doi.org/10.1111/bjh.12810
- Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease.Biol Blood Marrow Transpl. 2013; 19: 820-830https://doi.org/10.1016/j.bbmt.2013.02.010
- Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation.Ann N Y Acad Sci. 2012; 1266: 161-170https://doi.org/10.1111/j.1749-6632.2012.06606.x
- Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRalphabeta(+)/CD19(+)-depleted grafts.Blood Adv. 2018; 2: 263-270https://doi.org/10.1182/bloodadvances.2017012005
- Haploidentical CD3 or alpha/beta T-cell depleted HSCT in advanced stage sickle cell disease.Bone Marrow Transpl. 2019; 54: 1859-1867https://doi.org/10.1038/s41409-019-0550-0
- Familial haploidentical stem cell transplant in children and adolescents with high-risk sickle cell disease: a phase 2 clinical trial.JAMA Pedia. 2020; 174: 195-197https://doi.org/10.1001/jamapediatrics.2019.4715
- High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.Transplantation. 2009; 88: 1019-1024https://doi.org/10.1097/TP.0b013e3181b9d710
- Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation.Biol Blood Marrow Transpl. 2015; 21: 1392-1398https://doi.org/10.1016/j.bbmt.2015.05.001
- Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT.Bone Marrow Transpl. 2012; 47: 508-515https://doi.org/10.1038/bmt.2011.131
- Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets.J Hematol Oncol. 2015; 8: 84https://doi.org/10.1186/s13045-015-0182-9
- Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation.Blood. 2011; 118: 5957-5964https://doi.org/10.1182/blood-2011-06-362111
- The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure.Blood. 2010; 115: 2704-2708https://doi.org/10.1182/blood-2009-09-244525
- Anti-HLA antibodies in double umbilical cord blood transplantation.Biol Blood Marrow Transpl. 2011; 17: 1704-1708https://doi.org/10.1016/j.bbmt.2011.04.013
- The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation.Bone Marrow Transpl. 2018; 53: 521-534https://doi.org/10.1038/s41409-017-0062-8
- Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies.Biol Blood Marrow Transpl. 2013; 19: 647-652https://doi.org/10.1016/j.bbmt.2013.01.016
- Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion.Bone Marrow Transpl. 2005; 36: 555-556https://doi.org/10.1038/sj.bmt.1705070
- Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.Transplantation. 2000; 70: 887-895https://doi.org/10.1097/00007890-200009270-00006
- Rapid hematopoietic recovery with high levels of DSA in an unmanipulated haploidentical transplant patient.Transplantation. 2013; 95: e76-e77https://doi.org/10.1097/TP.0b013e318293fcda
- Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure.Br J Haematol. 2010; 151: 94-96https://doi.org/10.1111/j.1365-2141.2010.08305.x
- Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease.Haematologica. 2011; 96: 128-133https://doi.org/10.3324/haematol.2010.031013
- Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.Biol Blood Marrow Transpl. 2003; 9: 519-528https://doi.org/10.1016/s1083-8791(03)00192-7
- Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.Blood. 2017; 129: 1548-1556https://doi.org/10.1182/blood-2016-10-745711
- Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease.Biol Blood Marrow Transpl. 2017; 23: 2178-2183https://doi.org/10.1016/j.bbmt.2017.08.038
- Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.Biol Blood Marrow Transpl. 2015; 21: 900-905https://doi.org/10.1016/j.bbmt.2015.01.015
- Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.JAMA. 2014; 312: 48-56https://doi.org/10.1001/jama.2014.7192
- Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.N Engl J Med. 2009; 361: 2309-2317https://doi.org/10.1056/NEJMoa0904971
- Nonmyeloablative stem cell transplantation with alemtuzumab/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease.Biol Blood Marrow Transpl. 2016; 22: 441-448https://doi.org/10.1016/j.bbmt.2015.08.036
- Nonmyeloablative matched sibling donor hematopoietic cell transplantation in children and adolescents with sickle cell disease.Biol Blood Marrow Transpl. 2019; 25: 1179-1186https://doi.org/10.1016/j.bbmt.2019.02.011
- Cyclophosphamide-induced immunological tolerance: an overview.Immunobiology. 1996; 195: 129-139https://doi.org/10.1016/S0171-2985(96)80033-7
- Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation.Bone Marrow Transpl. 2000; 25: 401-404https://doi.org/10.1038/sj.bmt.1702151
- Mixed chimerism and transplant tolerance.Immunity. 2001; 14: 417-424https://doi.org/10.1016/s1074-7613(01)00122-4
- Induction of tolerance through mixed chimerism.Cold Spring Harb Perspect Med. 2014; 4a015529https://doi.org/10.1101/cshperspect.a015529
- Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation.Am J Transpl. 2015; 15: 695-704https://doi.org/10.1111/ajt.13091
- Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants.Blood. 2016; 127: 1539-1543https://doi.org/10.1182/blood-2015-12-685107
- High-dose sirolimus and immune-selective pentostatin plus cyclophosphamide conditioning yields stable mixed chimerism and insufficient graft-versus-tumor responses.Clin Cancer Res. 2015; 21: 4312-4320https://doi.org/10.1158/1078-0432.CCR-15-0340
- Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.Blood. 2014; 124: 344-353https://doi.org/10.1182/blood-2014-02-514778
- Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.J Exp Med. 1993; 178: 703-712https://doi.org/10.1084/jem.178.2.703
- Graft-versus-host disease.Lancet. 2009; 373: 1550-1561https://doi.org/10.1016/S0140-6736(09)60237-3
- Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation.Bone Marrow Transpl. 2014; 49: 126-130https://doi.org/10.1038/bmt.2013.143
- MHC-mismatched mixed chimerism augments thymic regulatory T-cell production and prevents relapse of EAE in mice.Proc Natl Acad Sci USA. 2015; 112: 15994-15999https://doi.org/10.1073/pnas.1521157112
- Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation.Blood. 2010; 115: 5401-5411https://doi.org/10.1182/blood-2009-11-253559
- Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.Bone Marrow Transpl. 1991; 8: 51-58
- Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.Bone Marrow Transpl. 2017; 52: 1241-1248https://doi.org/10.1038/bmt.2017.22
- Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations.Blood. 2006; 107: 2993-3001https://doi.org/10.1182/blood-2005-09-3623
- Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease.J Immunol. 2012; 189: 222-233https://doi.org/10.4049/jimmunol.1200677
- Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.J Immunol. 2013; 191: 488-499https://doi.org/10.4049/jimmunol.1300657
- High-dose sirolimus and immune-selective pentostatin plus cyclophosphamide conditioning yields stable mixed chimerism and insufficient graft-versus-tumor responses.Clin Cancer Res. 2015; 21: 4312
- Late effects of blood and marrow transplantation.Haematologica. 2017; 102: 614-625https://doi.org/10.3324/haematol.2016.150250
- Cardiac function after hematopoietic cell transplantation: an echocardiographic cross-sectional study in young adults treated in childhood.Pedia Blood Cancer. 2015; 62: 143-147https://doi.org/10.1002/pbc.25135
- Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation.Bone Marrow Transpl. 2021; 56: 2221-2230https://doi.org/10.1038/s41409-021-01298-7
- Prevalence of and risk factors for cardiac, pulmonary, and neurologic dysfunction following hematopoietic cell transplant for sickle cell disease: a STAR study.Transplant Cell Ther. 2022; 28: S49-S51https://doi.org/10.1016/s2666-6367(22)00219-6
- T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors.Haematologica. 2019; 104: e478-e482https://doi.org/10.3324/haematol.2018.215285
- CTLA4Ig in an extended schedule along with sirolimus improves outcome with a distinct pattern of immune reconstitution following post-transplantation cyclophosphamide-based haploidentical transplantation for hemoglobinopathies.Biol Blood Marrow Transpl. 2020; 26: 1469-1476https://doi.org/10.1016/j.bbmt.2020.05.005
- Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease.Bone Marrow Transpl. 2021; 56: 492-504https://doi.org/10.1038/s41409-020-01054-3
- Alternative donor: alphass/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.Hematol Oncol Stem Cell Ther. 2020; 13: 98-105https://doi.org/10.1016/j.hemonc.2019.12.006